Form 4: Supernus Pharmaceuticals CEO Reports Stock Transaction
Insider Transaction (Form 4)
Jack A. Khattar, President, CEO and a Director of Supernus Pharmaceuticals, Inc., reported multiple transactions in common stock on August 12, 2026.
Summary
- Option exercise/conversion: acquired 29,849 Common Stock on August 12, 2026; holds 1,270,993 after (Direct).
- Tax/exercise-price withholding: disposed of 12,642 Common Stock at $46.57 ($588,738) on August 12, 2026; holds 1,258,351 after (Direct).
- Option exercise/conversion: disposed of 29,849 Performance Share Unit on August 12, 2026 (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Jack A. Khattar — Director, Officer (President, CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-12 | Option exercise/conversion | Common Stock | 29,849 | — | — | 1,270,993 |
| 2026-08-12 | Tax/exercise-price withholding | Common Stock | 12,642 | $47 | $588.7K | 1,258,351 |
| 2026-08-12 | Option exercise/conversion | Performance Share Unit | 29,849 | — | — | 0 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-12 | Option exercise/conversion (29,849 shares) |
| 2026-08-12 | Tax/exercise-price withholding (12,642 shares) |
| 2026-08-12 | Option exercise/conversion (29,849 shares) |
Keywords
insider transaction, Form 4, SUPN, SUPERNUS PHARMACEUTICALS, INC., neutral, Jack A. Khattar
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.